Skip to main content
Erschienen in: Herzschrittmachertherapie + Elektrophysiologie 2/2015

01.06.2015 | Original contributions

Ventricular tachycardias in patients with pulmonary hypertension: an underestimated prevalence? A prospective clinical study

verfasst von: Dr. Dirk Bandorski, FESC/FACC, Dr. D. Erkapic, Dr. J. Stempfl, Dr. R. Höltgen, Prof. Dr. E. Grünig, Dr. J. Schmitt, Dr. R. Chasan, J. Grimminger, Prof. Dr. T. Neumann, Prof. Dr. C.W. Hamm, Prof. Dr. W. Seeger, Prof. Dr. H.A. Ghofrani, Dr. H. Gall

Erschienen in: Herzschrittmachertherapie + Elektrophysiologie | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Sudden cardiac death (SCD) accounts for approximately 30 % in patients with pulmonary arterial hypertension (PAH). The exact circumference for SCD in this patient population is still unclear. Malignant cardiac arrhythmias are reported to be rarely present. There are no systematic data concerning long-term electrocardiographic (ECG) recording in patients with PAH.

Objectives

We sought to investigate the rate of potentially relevant arrhythmias in patients with pulmonary hypertension (PH).

Methods

Consecutive patients without diagnosis of known cardiac arrhythmias followed in our outpatient clinic for PH were enrolled in the study. All patients underwent a 72-h Holter ECG. Clinical data, 6-min walk distance, laboratory values, and echocardiography were collected/performed.

Results

Ninety-two consecutive patients (New York Heart Association class (NYHA) III/IV: 65.2 %/5.4 %, PH Group 1: 35.9 %, Group 3: 10.9 %, Group 4: 28.3 %, Group 5: 2.2 %) were investigated. Relevant arrhythmias were newly detected in 17 patients: non-sustained ventricular tachycardia (n = 12), intermittent second-degree heart block (n = 1), intermittent third-degree heart block (n= 3), and atrial flutter (n = 1). Echocardiographic systolic pulmonary pressure and diameter of the right heart were elevated in patients with relevant arrhythmias. Right heart catheterization revealed higher pulmonary vascular resistance (672 vs. 542 dyn · s · cm−5, p = 0.247) and lower cardiac index (2.46 vs. 2.82 l/min/m2, p = 0.184).

Conclusions

Ventricular tachycardias occur more often in PH patients than previously reported. However, the prognostic relevance of non-sustained ventricular tachycardias in this cohort remains unclear. As a large number of PH patients die from SCD, closer monitoring, e.g., using implantable event recorders, might be useful to identify patients at high risk.
Literatur
1.
Zurück zum Zitat Opitz CF, Blindt R, Blumberg F et al (2011) Pulmonary hypertension: hemodynamic evaluation. Updated recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 154(Suppl 1):13–19CrossRef Opitz CF, Blindt R, Blumberg F et al (2011) Pulmonary hypertension: hemodynamic evaluation. Updated recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 154(Suppl 1):13–19CrossRef
2.
3.
Zurück zum Zitat Abe K, Toba M, Alzoubi A et al (2010) Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 121:2747–2754PubMedCrossRef Abe K, Toba M, Alzoubi A et al (2010) Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 121:2747–2754PubMedCrossRef
4.
Zurück zum Zitat Simonneau G, Gatzoulis MA, Adatia I et al (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D34–41PubMedCrossRef Simonneau G, Gatzoulis MA, Adatia I et al (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D34–41PubMedCrossRef
5.
Zurück zum Zitat Demerouti EA, Manginas AN, Athanassopoulos GD et al (2013) Complications leading to sudden cardiac death in pulmonary arterial hypertension. Respir Care 58:1246–1254PubMedCrossRef Demerouti EA, Manginas AN, Athanassopoulos GD et al (2013) Complications leading to sudden cardiac death in pulmonary arterial hypertension. Respir Care 58:1246–1254PubMedCrossRef
6.
Zurück zum Zitat Tongers J, Schwerdtfeger B, Klein G et al (2007) Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 153:127–132PubMedCrossRef Tongers J, Schwerdtfeger B, Klein G et al (2007) Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 153:127–132PubMedCrossRef
7.
Zurück zum Zitat Olsson KM, Nickel NP, Tongers J et al (2013) Atrial flutter and fibrillation in patients with pulmonary hypertension. Int J Cardiol 167:2300–2305PubMedCrossRef Olsson KM, Nickel NP, Tongers J et al (2013) Atrial flutter and fibrillation in patients with pulmonary hypertension. Int J Cardiol 167:2300–2305PubMedCrossRef
8.
Zurück zum Zitat Rottlaender D, Motloch LJ, Schmidt D et al (2012) Clinical impact of atrial fibrillation in patients with pulmonary hypertension. PLoS One 7:e33902PubMedCentralPubMedCrossRef Rottlaender D, Motloch LJ, Schmidt D et al (2012) Clinical impact of atrial fibrillation in patients with pulmonary hypertension. PLoS One 7:e33902PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Arya A, Piorkowski C, Sommer P et al (2007) Clinical implications of various follow up strategies after catheter ablation of atrial fibrillation. Pacing Clin Electrophysiol 30:458–462PubMedCrossRef Arya A, Piorkowski C, Sommer P et al (2007) Clinical implications of various follow up strategies after catheter ablation of atrial fibrillation. Pacing Clin Electrophysiol 30:458–462PubMedCrossRef
10.
Zurück zum Zitat Ghofrani HA, Distler O, Gerhardt F et al (2011) Treatment of pulmonary arterial hypertension (PAH): updated recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 154(Suppl 1):20–33CrossRef Ghofrani HA, Distler O, Gerhardt F et al (2011) Treatment of pulmonary arterial hypertension (PAH): updated recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 154(Suppl 1):20–33CrossRef
11.
Zurück zum Zitat Hoeper MM, Andreas S, Bastian A et al (2011) Pulmonary hypertension due to chronic lung disease: updated recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 154(Suppl 1):45–53CrossRef Hoeper MM, Andreas S, Bastian A et al (2011) Pulmonary hypertension due to chronic lung disease: updated recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 154(Suppl 1):45–53CrossRef
12.
Zurück zum Zitat Wilkens H, Lang I, Behr J et al (2011) Chronic thromboembolic pulmonary hypertension (CTEPH): updated recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 154(Suppl 1):54–60CrossRef Wilkens H, Lang I, Behr J et al (2011) Chronic thromboembolic pulmonary hypertension (CTEPH): updated recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 154(Suppl 1):54–60CrossRef
13.
Zurück zum Zitat n.a. (1996) Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 93:1043–1065CrossRef n.a. (1996) Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 93:1043–1065CrossRef
14.
Zurück zum Zitat European Society of Cardiology (ESC), European Heart Rhythm Association (EHRA), Brignole M, Auricchio A, Baron-Esquivias G et al (2013) 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace 15:1070–1118PubMedCrossRef European Society of Cardiology (ESC), European Heart Rhythm Association (EHRA), Brignole M, Auricchio A, Baron-Esquivias G et al (2013) 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace 15:1070–1118PubMedCrossRef
15.
Zurück zum Zitat Zipes DP, Camm AJ, Borggrefe M et al (2006) ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114:e385–e484PubMedCrossRef Zipes DP, Camm AJ, Borggrefe M et al (2006) ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114:e385–e484PubMedCrossRef
16.
Zurück zum Zitat Baumgartner H, Bonhoeffer P, De Groot NM, Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC), Association for European Paediatric Cardiology (AEPC), ESC Committee for Practice Guidelines (CPG) et al (2010) ESC guidelines for the management of grown-up congenital heart disease, new version 2010. Eur Heart J 3:2915–2957 Baumgartner H, Bonhoeffer P, De Groot NM, Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC), Association for European Paediatric Cardiology (AEPC), ESC Committee for Practice Guidelines (CPG) et al (2010) ESC guidelines for the management of grown-up congenital heart disease, new version 2010. Eur Heart J 3:2915–2957
17.
Zurück zum Zitat n.a. (1996) Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 1:354–381 n.a. (1996) Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 1:354–381
18.
Zurück zum Zitat Crapo RO, Casburi R, Coates AL et al (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117CrossRef Crapo RO, Casburi R, Coates AL et al (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117CrossRef
19.
Zurück zum Zitat Rudski LG, Lai WW, Afilalo J et al (2010) Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 23:685–713PubMedCrossRef Rudski LG, Lai WW, Afilalo J et al (2010) Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 23:685–713PubMedCrossRef
20.
Zurück zum Zitat Lang RM, Bierig M, Devereux RB et al (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463PubMedCrossRef Lang RM, Bierig M, Devereux RB et al (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463PubMedCrossRef
21.
Zurück zum Zitat Baumgartner H, Hung J, Bermejo J et al (2009) Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J Echocardiogr 10:1–25PubMedCrossRef Baumgartner H, Hung J, Bermejo J et al (2009) Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J Echocardiogr 10:1–25PubMedCrossRef
22.
Zurück zum Zitat Zoghbi WA, Enriquez-Sarano M, Foster E et al (2003) Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16:777–802PubMedCrossRef Zoghbi WA, Enriquez-Sarano M, Foster E et al (2003) Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16:777–802PubMedCrossRef
23.
Zurück zum Zitat Folino AF, Bobbo F, Schiraldi C et al (2003) Ventricular arrhythmias and autonomic profile in patients with pulmonary hypertension. Lung 181:312–328CrossRef Folino AF, Bobbo F, Schiraldi C et al (2003) Ventricular arrhythmias and autonomic profile in patients with pulmonary hypertension. Lung 181:312–328CrossRef
24.
Zurück zum Zitat Fauchier L, Babuty D, Melin A, Bonnet P, Cosnay P, Fauchier JP (2004) Heart rate variability in severe right or left heart failure: the role of pulmonary hypertension and resistances. Eur J Heart Fail 6:181–185PubMedCrossRef Fauchier L, Babuty D, Melin A, Bonnet P, Cosnay P, Fauchier JP (2004) Heart rate variability in severe right or left heart failure: the role of pulmonary hypertension and resistances. Eur J Heart Fail 6:181–185PubMedCrossRef
25.
Zurück zum Zitat Sulica R, Thiagarajah P, Hanon S et al (2009) Low prevalence of arrhythmias in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 179:A4902 (Abstract) Sulica R, Thiagarajah P, Hanon S et al (2009) Low prevalence of arrhythmias in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 179:A4902 (Abstract)
26.
Zurück zum Zitat Bass EB, Curtiss EI, Arena VC et al (1990) The duration of Holter monitoring in patients with syncope. Is 24 hours enough? Arch Intern Med 150:1073–1078PubMedCrossRef Bass EB, Curtiss EI, Arena VC et al (1990) The duration of Holter monitoring in patients with syncope. Is 24 hours enough? Arch Intern Med 150:1073–1078PubMedCrossRef
27.
Zurück zum Zitat Ruiz MJ, Gonzalez-Mansilla A, Escribano P et al (2011) Clinical implications of supraventricular arrhythmias in patients with severe pulmonary arterial hypertension. Int J Cardiol 146:105–106CrossRef Ruiz MJ, Gonzalez-Mansilla A, Escribano P et al (2011) Clinical implications of supraventricular arrhythmias in patients with severe pulmonary arterial hypertension. Int J Cardiol 146:105–106CrossRef
28.
Zurück zum Zitat So PP, Davies RA, Chandy G et al (2012) Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension. Am J Cardiol 109:1504–1509PubMedCrossRef So PP, Davies RA, Chandy G et al (2012) Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension. Am J Cardiol 109:1504–1509PubMedCrossRef
29.
Zurück zum Zitat Radjev A, Garan H, Biviano A (2012) Arrhythmias in pulmonary arterial hypertension. Prog Cardiovasc Dis 55:180–186CrossRef Radjev A, Garan H, Biviano A (2012) Arrhythmias in pulmonary arterial hypertension. Prog Cardiovasc Dis 55:180–186CrossRef
30.
Zurück zum Zitat Bjornsson J, Edwards WD (1985) Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc 60:16–25PubMedCrossRef Bjornsson J, Edwards WD (1985) Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc 60:16–25PubMedCrossRef
31.
Zurück zum Zitat Hoeper MM, Galié N, Murali S et al (2002) Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 165:341–344PubMedCrossRef Hoeper MM, Galié N, Murali S et al (2002) Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 165:341–344PubMedCrossRef
32.
Zurück zum Zitat Umar S, Lee JH, de Lange E et al (2012) Spontaneous ventricular fibrillation in right ventricular failure secondary to chronic pulmonary hypertension. Circ Arrhythm Electrophysiol 5:181–190PubMedCentralPubMedCrossRef Umar S, Lee JH, de Lange E et al (2012) Spontaneous ventricular fibrillation in right ventricular failure secondary to chronic pulmonary hypertension. Circ Arrhythm Electrophysiol 5:181–190PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Antzelevitsch C (2005) Role of transmural dispersion of depolarization in the genesis of drug-induced torsades de pointes. Heart Rhythm 2:9–15CrossRef Antzelevitsch C (2005) Role of transmural dispersion of depolarization in the genesis of drug-induced torsades de pointes. Heart Rhythm 2:9–15CrossRef
34.
Zurück zum Zitat Lammers AE, Munnery E, Hislop AA et al (2010) Heart rate variability predicts outcome in children with pulmonary arterial hypertension. Int J Cardiol 142:159–165PubMedCrossRef Lammers AE, Munnery E, Hislop AA et al (2010) Heart rate variability predicts outcome in children with pulmonary arterial hypertension. Int J Cardiol 142:159–165PubMedCrossRef
35.
Zurück zum Zitat Can MM, Kaymaz C, Pochi N et al (2013) Impact of pulmonary arterial hypertension and its therapy on indices of heart rate variability. Med Glas (Zenica) 10:249–253 Can MM, Kaymaz C, Pochi N et al (2013) Impact of pulmonary arterial hypertension and its therapy on indices of heart rate variability. Med Glas (Zenica) 10:249–253
36.
Zurück zum Zitat Yi HT, Hsieh YC, Wu TJ et al (2014) Heart rate variability parameters and ventricular arrhythmia correlate with pulmonary arterial pressure in adult patients with idiopathic pulmonary arterial hypertension. Heart Lung. pii: S0147-9563(14)00150-2. doi:10.1016/j.hrtlng.2014.05.010 Yi HT, Hsieh YC, Wu TJ et al (2014) Heart rate variability parameters and ventricular arrhythmia correlate with pulmonary arterial pressure in adult patients with idiopathic pulmonary arterial hypertension. Heart Lung. pii: S0147-9563(14)00150-2. doi:10.1016/j.hrtlng.2014.05.010
37.
Zurück zum Zitat Bienias P, Kostrubiec M, Rymarczyk Z et al (2014) Severity of arterial and chronic thromboembolic pulmonary hypertension is associated with impairment of heart rate turbulence. Ann Noninvasive Electrocardiol. doi:10.1111/anec.12169 Bienias P, Kostrubiec M, Rymarczyk Z et al (2014) Severity of arterial and chronic thromboembolic pulmonary hypertension is associated with impairment of heart rate turbulence. Ann Noninvasive Electrocardiol. doi:10.1111/anec.12169
38.
Zurück zum Zitat Horner SM, Murphy CF, Coen B et al (1996) Contribution to heart rate variability by mechanoelectric feedback. Stretch of the sinoatrial node reduces heart rate variability. Circulation 94:1762–1767PubMedCrossRef Horner SM, Murphy CF, Coen B et al (1996) Contribution to heart rate variability by mechanoelectric feedback. Stretch of the sinoatrial node reduces heart rate variability. Circulation 94:1762–1767PubMedCrossRef
39.
Zurück zum Zitat Flapan AD, Nolan J, Neilson JM et al (1992) Effect of captopril on cardiac parasympathetic activity in chronic cardiac failure secondary to coronary artery disease. Am J Cardiol 69:532–535PubMedCrossRef Flapan AD, Nolan J, Neilson JM et al (1992) Effect of captopril on cardiac parasympathetic activity in chronic cardiac failure secondary to coronary artery disease. Am J Cardiol 69:532–535PubMedCrossRef
40.
Zurück zum Zitat Binkley PF, Haas GJ, Starling RC et al (1993) Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. J Am Coll Cardiol 21:655–661PubMedCrossRef Binkley PF, Haas GJ, Starling RC et al (1993) Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. J Am Coll Cardiol 21:655–661PubMedCrossRef
Metadaten
Titel
Ventricular tachycardias in patients with pulmonary hypertension: an underestimated prevalence? A prospective clinical study
verfasst von
Dr. Dirk Bandorski, FESC/FACC
Dr. D. Erkapic
Dr. J. Stempfl
Dr. R. Höltgen
Prof. Dr. E. Grünig
Dr. J. Schmitt
Dr. R. Chasan
J. Grimminger
Prof. Dr. T. Neumann
Prof. Dr. C.W. Hamm
Prof. Dr. W. Seeger
Prof. Dr. H.A. Ghofrani
Dr. H. Gall
Publikationsdatum
01.06.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Herzschrittmachertherapie + Elektrophysiologie / Ausgabe 2/2015
Print ISSN: 0938-7412
Elektronische ISSN: 1435-1544
DOI
https://doi.org/10.1007/s00399-015-0364-8

Weitere Artikel der Ausgabe 2/2015

Herzschrittmachertherapie + Elektrophysiologie 2/2015 Zur Ausgabe

Schwerpunkt

ICD-Elektroden

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.